Eurofins Reinforces Its Footprint in Discovery Pharmacology with the Acquisition of Villapharma in Spain
December 29 2016 - 8:36AM
Business Wire
Regulatory News:
Eurofins Scientific (Paris:ERF) (EUFI.PA) a world leader in
providing analytical support to the global pharmaceutical industry,
announces the signing of an agreement to acquire Villapharma
Research SL (“Villapharma”) in Spain. The transaction is expected
to close in February 2017, upon fulfilment of customary closing
conditions.
Villapharma provides organic synthesis and medicinal chemistry
services to global pharmaceutical and biotech companies for the
discovery and optimization of potential new drug candidates.
Founded in 2003, Villapharma employs 86 staff at its laboratory in
Murcia and runs a research outsourcing business model for its
clients. The company expects to generate more than EUR 6m of
revenues in 2016 with EBITDA margins compatible with Group
objective.
Villapharma’s offering is complementary to Eurofins’ existing
competencies as a leading provider of pharmaceutical discovery
services, currently focused primarily on safety pharmacology, ADME
and target pathways. The transaction therefore expands the Group’s
services into a more comprehensive offering and further strengthens
its service proposition for the pharma/biotech industry.
Comment from Dr. Gilles Martin, Eurofins CEO: “The
addition of Villapharma adds another spectrum of new services that
Eurofins can now offer to our clients. To benefit from the trend in
the discovery pharmacology field for outsourcing to CROs, Eurofins
is expanding its portfolio and footprint in this industry. This
transaction is another demonstration of Eurofins’ commitment to
provide the most comprehensive portfolio of laboratory services in
the industry.”
Comment from Dr. José Manuel Villalgordo, Villapharma
Research CEO: “With the integration of Villapharma into the large
Eurofins group, the company expands its portfolio of services from
hit finding to pre-clinical drug candidates.”
For more information, please visit
www.eurofins.com or contact:
Notes for the editor:
Eurofins – a global leader in bio-analysisEurofins
believes it is the world leader in food, environment and
pharmaceutical products testing and that it is also one of the
global independent market leaders in certain testing and laboratory
services for agroscience, genomics and discovery pharmacology and
for supporting clinical studies. In addition, Eurofins is one of
the significant emerging players in specialty clinical diagnostic
testing in Europe and the USA.
With 25,000 staff in more than 250 laboratories across 39
countries, Eurofins offers a portfolio of over 130,000 validated
analytical methods for evaluating the safety, identity,
composition, authenticity, origin, traceability and purity of
biological substances and products, as well as for innovative
clinical diagnostic. The Group provides its customers with
high-quality services, accurate results on time and expert advice
by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities and healthcare
practitioners around the world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgement
of Eurofins Scientific’ management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161229005189/en/
Eurofins ScientificChristina Shasserre, Phone: +1 636 362
7100President, Eurofins Pharma BioAnalytical ServicesE-mail:
christinashasserre@eurofins.comorInvestor RelationsEurofins
ScientificPhone: + 32 2 766 1620E-mail: ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Apr 2023 to Apr 2024